Steven J Wiley

US Patent:

20010010925, Aug 2, 2001

Filed:

Nov 17, 1997

Appl. No.:

08/971317

Inventors:

STEVEN R. WILEY - LIBERTYVILLE IL, US

International Classification:

A01N037/18
A61K038/00
C12Q001/68
G01N033/53
G01N033/567
C07H021/04
A61K031/70
A01N043/04
C12P021/06
A61K039/00

US Classification:

435/069100, 536/023500, 536/023510, 530/324000, 514/044000, 424/198100, 424/203100, 424/185100, 435/007100, 530/387900, 530/388240, 435/007200, 514/002000, 435/320100, 435/006000

Abstract:

An isolated clone consisting of sequences transcribed from the TNF-delta gene is disclosed. Also provided are human polypeptides translated from said TNF-delta sequences and a procedure for producing such polypeptide by recombinant techniques. Also provided are a procedure for producing soluble biologically active TNF-delta, which may be used to treat deficiencies of TNF-delta and diseases conditions ameliorated by TNF-delta. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat TNF-delta associated diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognosticate, stage and monitor conditions and diseases attributable to TNF-delta, especially inflammation. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases associated with TNF-delta, including but not limited to inflammation is also disclosed. Illustrative sequences and clone designations for TNF-delta are provided.

US Patent:

61717878, Jan 9, 2001

Filed:

Jun 26, 1997

Appl. No.:

8/883086

Inventors:

Steven R. Wiley - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12Q 168

US Classification:

435 6

Abstract:

An isolated clone consisting of sequences transcribed from the TNF-gamma gene. Also provided are human polypeptides translated from said TNF-gamma sequences and a procedure for producing such polypeptide by recombinant techniques. Also provided are a procedure for producing soluble biologically active TNF-gamma, which may be used to treat deficiencies of TNF-gamma and diseases conditions ameliorated by TNF-gamma. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat TNF-gamma associated diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognosticate, stage and monitor conditions and diseases attributable to TNF-gamma, especially inflammation. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases associated with TNf-gamma, including but not limited to inflammation. Illustrative sequences and clone designations for TNF-gamma are provided.

US Patent:

62076426, Mar 27, 2001

Filed:

Jun 26, 1998

Appl. No.:

9/105343

Inventors:

Steven R. Wiley - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K38/18
7
C07K14/46

US Classification:

514 12

Abstract:

An isolated clone consisting of sequences transcribed from the TREPA gene. Also provided are human polypeptides translated from said TREPA sequences and a procedure for producing such polypeptide by recombinant techniques. Also provided are a procedure for producing soluble biologically active TREPA, which may be used to treat deficiencies of TREPA and diseases conditions ameliorated by TREPA. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat TREPA-associated diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognosticate, stage and monitor conditions and diseases attributable to TREPA, especially inflammation. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases associated with TREPA, including but not limited to inflammation. Illustrative sequences and clone designations for TREPA are provided.